Agentix Corp. Reports No Revenue and Net Loss of $567,048 for Fiscal Year Ending March 31, 2025

Agentix Corp., a clinical-stage biotechnology company focused on developing therapeutics for metabolic diseases, reported no revenue for the fiscal year ending March 31, 2025, consistent with the previous year. The company incurred a net loss of $567,048, a slight improvement from the $585,154 loss reported in the prior fiscal year. Total operating expenses decreased to $513,251 from $744,810, primarily due to a significant reduction in general and administrative expenses, which fell from $346,543 to $69,898. This decrease was attributed to a reduction in royalty fees related to patents incurred in the prior period.

The company’s financial position remains precarious, with an accumulated deficit of $6,521,528 as of March 31, 2025, and total liabilities amounting to $3,204,523. The liabilities include $1,932,438 owed to related parties, reflecting the company's reliance on loans and advances from shareholders to sustain operations. Cash on hand at the end of the fiscal year was $4,477, indicating a critical need for additional funding to support ongoing operations and development activities.

Strategically, Agentix has made significant moves to enhance its operational capabilities. The establishment of Agentix Australia Pty Ltd in September 2022 aims to facilitate the development of its key assets while participating in a tax rebate program for biotechnology activities in Australia. The company is advancing two primary drug candidates, AGTX-2004 and AGTX-2003, both of which are designed to target peripheral cannabinoid receptors without crossing the blood-brain barrier. AGTX-2004 has received FDA clearance for an Investigational New Drug application and is preparing for a Phase 1 clinical trial, while AGTX-2003 is undergoing additional animal studies in preparation for its own IND application.

Despite these developments, Agentix faces challenges in scaling its operations. The company reported no full-time employees as of March 31, 2025, with operations managed by one of its directors. The lack of a functioning audit committee and independent oversight has raised concerns about the effectiveness of internal controls, which could impact financial reporting. Looking ahead, Agentix acknowledges the need for substantial funding to continue its business plan and is exploring options for equity and debt financing. However, the company cautions that without successful fundraising, its ability to continue operations may be jeopardized.